Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia

Medical Decision Making

Volumn 38, Issue 1_suppl, 2018, Pages 54S-65S

  van den Broek, Jeroen J ^a   van Ravesteyn, Nicolien T ^a   Heijnsdijk, Eveline A ^a   de Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

breast cancer epidemiology; microsimulation model; risk based breast cancer screening

Indexed keywords

ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; BIOLOGICAL MODEL; BREAST TUMOR; CANCER STAGING; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FEMALE; HUMAN; MAMMOGRAPHY; NETHERLANDS; PATHOLOGY; PROCEDURES; PROTO ONCOGENE; RISK ASSESSMENT; TREATMENT OUTCOME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMPUTER SIMULATION; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; HUMANS; MAMMOGRAPHY; MODELS, BIOLOGICAL; NEOPLASM STAGING; NETHERLANDS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85040597336     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17711928     Document Type: Article

References (37)

1. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed. 1985;20(1):79–93.
2. Boer R, de Koning H, van Oortmarssen G, Warmerdam P, van der Maas P. Stage distribution at first and repeat examinations in breast cancer screening. J Med Screen. 1999;6(3):132–8.
3. Mandelblatt JS, Near AM, Miglioretti DL. Common model inputs used in CISNET collaborative breast cancer modeling. Med Decis Making. 2018;38(1S):9–23.
4. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am. 1992;30(1):187–210.
5. Tabar L, Fagerberg G, Day NE, Duffy SW. The Swedish two-county trial of mammographic screening for breast cancer: recent results on mortality and tumor characteristics. Pathol Biol (Paris). 1992;39(9):846.
6. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006;(36):56–65.
7. Clemmesen J. Carcinoma of the breast; results from statistical research. Br J Radiol. 1948;21(252):583–90.
8. Weedon-Fekjaer H, Bakken K, Vatten LJ, Tretli S. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ. 2012;344:e299.
9. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;(36):19–25.
10. Gangnon RE, Sprague BL, Stout NK. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. Cancer Epidemiol Biomarkers Prev. 2015;24(6):905–12.
11. de Gelder R, Fracheboud J, Heijnsdijk EA. Digital mammography screening: weighing reduced mortality against increased overdiagnosis. Prev Med. 2011;53(3):134–40.
12. van Ravesteyn NT, van den, Broek JJ, Li X. Modeling ductal carcinoma in situ (DCIS): an overview of CISNET model approaches. Med Decis Making. 2018;38(1S):126–139.
13. Munoz D, Near AM, van Ravesteyn NT. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106(11).
14. Berry DA, Cronin KA, Plevritis SK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.
15. Feuer EJ. Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem. J Natl Cancer Inst Monogr. 2006;(36):2–6.
16. Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr. 2006;(36):26–9.
17. Cronin KA, Yu B, Krapcho M. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16(6):701–12.
18. Stout NK, Lee SJ, Schechter CB. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106(6):dju092.
19. Early Breast Cancer Trialists’ Collaborative Group, Peto R, Davies C. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.
20. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6(6):e21030.
21. Barton RR, Ivey JS. Nelder-Mead simplex modifications for simulation optimization. Management Sci. 1996;42:954–73.
22. Tan SYGL, Van Oortmarssen GJ, Piersma N. Estimating parameters of a microsimulation model for breast cancer screening using the score function method. Ann Oper Res. 2003;119(1):43–61.
23. Eddy DM, Hollingworth W, Caro JJ. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733–43.
24. van Ravesteyn NT, Miglioretti DL, Stout NK. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012;156(9):609–17.
25. Mandelblatt JS, Stout NK, Schechter CB. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Intern Med. 2016;164(4):215–25.
26. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol. 2015;16(9):1123–32.
27. Breast Screening Frequency Trial Group. The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. Eur J Cancer. 2002;38(11):1458–64.
28. van Ravesteyn NT, Heijnsdijk EA, Draisma G, de Koning HJ. Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals. Br J Cancer. 2011;105(7):1082–8.
29. Mandelblatt J, van Ravesteyn N, Schechter C. Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention. Cancer. 2013;119(14):2541–8.
30. Sprague BL, Stout NK, Schechter C. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015;162(3):157–66.
31. Miglioretti DL, Lange J, van den Broek JJ. Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med. 2016;164(4):205–14.
32. van Ravesteyn NT, Schechter CB, Near AM. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev. 2011;20(1):112–22.
33. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69.
34. Aiello EJ, Buist DS, White E, Porter PL. Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2005;14(3):662–8.
35. Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA. Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: Collaborative modeling of screening outcomes. Ann Intern Med. 2016;165(10):700-12.
36. Mavaddat N, Pharoah PD, Michailidou K. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107(5):djv036.
37. van Luijt PA, Heijnsdijk EA, Fracheboud J. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res. 2016;18(1):47.